Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
- Chugai CEO Questions Off-Year Price Cuts for On-Patent Meds
December 21, 2022
- Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
- Chugai Eyes Submission of Oral GLP-1 Agent in 2025-2026: R&D Briefing
December 20, 2022
- Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- R&D Head Shiro Akinaga Becomes NanoCarrier President
December 19, 2022
- SymBio, Eagle Pharma Sue Towa over Treakisym Patent in Japan
December 19, 2022
- Sosei, Lilly in Drug Discovery Collab for Diabetes and Metabolic Diseases
December 19, 2022
- Astellas’s Zolbetuximab Makes Marks in Another PIII Gastric Cancer Study
December 19, 2022
- Pharma Industry Mixed on Off-Year Drug Price Revision Plan for FY2023
December 19, 2022
- PeptiDream, Takeda Expected to Select 1st Oligo-PDC Candidate in 2023
December 16, 2022
- Eisai, Washington University to Team Up on Neurodegenerative Disease Therapies
December 16, 2022
- Twymeeg Most Promoted Drug in GP Market for 4 Months Straight in October: Intage
December 16, 2022
- Sunovion Offloads Lunesta to Woodward Pharma
December 16, 2022
- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
- Daiichi Sankyo Plots Further Growth with Enhertu Follow-Ons, Eyes Next-Gen ADCs
December 15, 2022
- Bayer Files Xarelto for Congenital Heart Disease after Fontan Procedure in Japan
December 15, 2022
- Total Sales of 25 Japan Drug Makers Up 12.9% in 1st Half, Global Players Fare Well While SMEs Falter
December 15, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…